Novavax Says Its Vaccine is 90% Effective Against Coronavirus

Biotech company Novavax said today that its COVID-19 vaccine has been shown to be 90.4% safe and effective overall in phase 3 clinical trials for nearly 30,000 participants across the United States and Mexico.

Also, it was found that the two-dose vaccine is 100% effective in preventing moderate and severe symptoms and 93% is effective against some mutations.

The company said it plans to file an application for authorization with the Food and Drug Administration in the third quarter of this year.